Elevation nails down $30M for COPD aerosol treatment; Ikaria recalls nitric oxide/inhalation product;

> Elevation Pharmaceuticals has closed $30 million in Series B financing to fund further development of its new aerosol therapy to treat chronic obstructive pulmonary disease, for use in a nebulizer. Release

> The FDA has granted orphan drug designation to Dutch company Amsterdam Molecular Therapeutics for its gene therapy program to treat hemophilia B; in early testing, it appears to reduce the need for protein replacement treatment. Release

> Addenbrooke's Hospital in Cambridge, U.K. has recruited 1,000 diabetic patients to a clinical trial comparing the effectiveness of pumps that deliver insulin directly into the body with the effectiveness of daily multiple injections, the BBC reports. Video

> Ikaria has issued a class I FDA recall notice for its Inomax DS nitric oxide/inhalation product, which treats hypoxic respiratory failure relating to hypertension in infants; health professionals have been notified and the problem corrected, the company said.  Release

> French regulators have approved United Therapeutics' use of Remodulin (treprostinil) by continuous subcutaneous infusion to treat pulmonary arterial hypertension. Story

> Arrowhead Research ($ARWR) has gained FDA clearance to begin a Phase I clinical trial of its obesity drug AdipotideTM, a nanomedicine treatment that targets and kills blood vessels supplying white fat tissue. Story

Suggested Articles

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.